Analysts Issue Forecasts for TOI Q2 Earnings

The Oncology Institute, Inc. (NASDAQ:TOI) – Analysts at Noble Financial issued their Q2 2025 earnings per share estimates for Oncology Institute in a research report issued to clients and investors on Wednesday, July 23rd. Noble Financial analyst R. Leboyer forecasts that the company will post earnings of ($0.14) per share for the quarter. Noble Financial currently has a “Outperform” rating and a $8.00 target price on the stock. Noble Financial also issued estimates for Oncology Institute’s Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.28) EPS.

Other equities research analysts have also recently issued research reports about the stock. BTIG Research began coverage on shares of Oncology Institute in a research report on Thursday, May 15th. They issued a “buy” rating and a $7.00 price objective for the company. B. Riley assumed coverage on shares of Oncology Institute in a research note on Wednesday, July 16th. They set a “buy” rating and a $6.00 price target on the stock.

Oncology Institute Price Performance

Shares of Oncology Institute stock opened at $3.62 on Monday. The stock has a market capitalization of $323.03 million, a price-to-earnings ratio of -5.17 and a beta of 0.02. The firm’s 50-day moving average price is $2.86 and its two-hundred day moving average price is $1.92. The company has a current ratio of 1.79, a quick ratio of 1.59 and a debt-to-equity ratio of 14.58. Oncology Institute has a 1-year low of $0.13 and a 1-year high of $4.03.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. The company had revenue of $104.41 million for the quarter. Oncology Institute had a negative return on equity of 445.02% and a negative net margin of 15.38%.

Insider Activity

In other news, Director Growth I. L.P. M33 sold 1,796,468 shares of the firm’s stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $2.71, for a total transaction of $4,868,428.28. Following the completion of the transaction, the director directly owned 14,624,233 shares of the company’s stock, valued at $39,631,671.43. This trade represents a 10.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brad Hively sold 1,976,137 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total transaction of $5,671,513.19. Following the transaction, the director owned 603,501 shares of the company’s stock, valued at $1,732,047.87. The trade was a 76.61% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,726,137 shares of company stock valued at $13,379,013 over the last ninety days. 8.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its holdings in shares of Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after purchasing an additional 109,769 shares during the period. Virtu Financial LLC bought a new stake in Oncology Institute in the fourth quarter valued at approximately $41,000. Renaissance Technologies LLC raised its stake in Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock valued at $56,000 after buying an additional 12,000 shares during the period. XTX Topco Ltd lifted its position in shares of Oncology Institute by 49.5% in the first quarter. XTX Topco Ltd now owns 55,698 shares of the company’s stock valued at $63,000 after buying an additional 18,448 shares during the last quarter. Finally, Citizens Financial Group Inc. RI bought a new position in shares of Oncology Institute during the 1st quarter worth approximately $71,000. Institutional investors and hedge funds own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.